Medical Condition News

RSS

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

According to the American Cancer Society, more than one million people are diagnosed with cancer each year. In the United States, about 1 out of every 2 men and 1 out of every 3 women will have some type of cancer at some point during their lifetime. The sooner a cancer is detected and treatment begins, the better the patient’s chances for survival.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia(TM) campaign through a rebranded Web site and a new community on Facebook®. People living with hemophilia face many daily challenges, and Novo Nordisk is committed to helping this community realize that there is also a lifetime of possibilities.

From Novo Nordisk 31 Oct 2009

New diagnostic test for detecting colorectal cancer

GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.

31 Oct 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

31 Oct 2009

Innovative optical system to study the complex mechanisms that lead to sudden cardiac arrest developed

A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

New teleneurology medicine program to provide 24-hour emergency services launched

Rural and small, suburban hospitals in North Carolina and Virginia can now provide a higher level of emergency stroke and critical neurology care, 24 hours a day, 365 days a year, as part of a new teleneurology medicine program announced Oct. 26, 2009, by Forsyth Medical Center (FMC).

31 Oct 2009

Genetic susceptibility study for Barrett's esophagus and esophageal adenocarcinoma awarded $7.9M grant

Thomas Vaughan, M.D., head of the Epidemiology Program in the Public Health Sciences Division of Fred Hutchinson Cancer Research Center, has received a three-year, $7.9 million grant from the National Cancer Institute to study genetic susceptibility for Barrett's esophagus and esophageal adenocarcinoma, a rapidly fatal cancer whose incidence has increased more than 500 percent in the past 30 years, faster than any other cancer in the United States.

31 Oct 2009

NYBC and its divisions call upon the community to join the fight against cancer by donating blood

November is both Pancreatic Cancer Awareness Month and Lung Cancer Awareness Month, and New York Blood Center (NYBC) and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn/Staten Island, and New Jersey call upon the community to join the fight against cancer by donating blood today.

31 Oct 2009

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

31 Oct 2009

FDA approves an expanded indication for BYETTA injection

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.

30 Oct 2009

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

BSD Medical Corporation today announced that published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer.

30 Oct 2009

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Charles Drew University has been awarded $9.8 million from three major national funders to support the university's long-term, UCLA partnership aimed at reducing the risk of cancer among minorities in poor and disadvantaged communities.

30 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

Medical Condition News

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

Quintiles and Eisai partner to develop potential oncology products

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

New diagnostic test for detecting colorectal cancer

Immunotherapy, a new therapeutic area to destroy tumor cells

Study: Gene therapy can reduce symptoms of Huntington's disease

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Innovative optical system to study the complex mechanisms that lead to sudden cardiac arrest developed

Geron plans to advance clinical program for spinal cord injury

New teleneurology medicine program to provide 24-hour emergency services launched

Genetic susceptibility study for Barrett's esophagus and esophageal adenocarcinoma awarded $7.9M grant

NYBC and its divisions call upon the community to join the fight against cancer by donating blood

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

FDA approves an expanded indication for BYETTA injection

Data from multiple clinical and preclinical studies evaluating Hematide announced

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News